Caliper Announces Issuance of Five New Microfluidic Patents

Caliper is pursuing an aggressive intellectual property strategy to establish a comprehensive proprietary estate encompassing all aspects of microfluidic technology. Caliper's patent portfolio derives from its own innovation as well as inventions licensed exclusively to Caliper from other micro...

Full description

Saved in:
Bibliographic Details
Published inPR Newswire p. 1
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 22.11.2000
Subjects
Design
Experiments
Intellectual property
Laboratories
Proprietary
Trademarks
California
Online AccessGet full text

Cover

More Information
Summary:Caliper is pursuing an aggressive intellectual property strategy to establish a comprehensive proprietary estate encompassing all aspects of microfluidic technology. Caliper's patent portfolio derives from its own innovation as well as inventions licensed exclusively to Caliper from other microfluidic technology leaders. Today, Caliper has 69 issued U.S. patents, with 164 patent applications filed and another 17 patents allowed. These patents broadly cover microfluidic technology, instrumentation, applications, manufacturing technology and control and analysis software. Note: This news release contains a forward-looking statement regarding Caliper's expectations regarding the timing of the release of its cell-based assays for use on the Agilent 2100 Bioanalyzer. The actual timing of the release is subject to risks and uncertainties, including the fact that these assays are still in development, and unanticipated technical problems may arise that could delay the date of delivery of these products, or may prevent Caliper from completing these products. In addition, the foregoing discussion of newly issued microfluidics patents involves risks and uncertainty, including the risks: that Caliper may need to initiate lawsuits to protect or enforce its patents, which would be expensive and, if Caliper loses, may cause it to lose some or all of its intellectual property rights, which would reduce its ability to compete in the market. These and other risks related to Caliper are detailed in Caliper's Annual Report on Form 10-K filed with the SEC dated March 24, 2000.